Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by juniper88on May 03, 2019 10:36am

132 Views

Post# 29706270

RE:RE:Weekly Sales Update from Bloomberg

juniper88 wrote:

SPCEO1 wrote: The 4 week moving average fell to 511 from 567 last week. But this is likely a statistical fluke as April's month-end fell in the middle of a week, resulting in the best week ever falling off the 4 week moving average and it being replaced by just a "good" week. In past months, the week around the month end captured the largest number of prescriptions. My guess is the 4 week moving average will jump next week when we get another good week and a really low week falls off the 4 week moving average.

If you try to adjust for this mid-week month-end and use a 5 week moving average, it rose to 584 from 549.

Bloomberg has yet to show a price increase for Trogarzo following its one eyar anniversery earlier this week but I imagine it is not super prompt in picking price increases up.

That would make next week's Bloomberg numbers more telling. If we don't see a big increase then either the Bloomberg numbers are worthless or sales have stalled.

I beleive the same for Taimed's revenue numbers. Yes, there can be some fluctuations in the numbers but really for a ramping up drug, we should be seeing some good increases.

So far what I am seeing is a Egrifta 2.0, which I believe is rather dissappointing for a life saving drug. We have heard stats of about 6000 people dying of AIDS in the states per year. And we are struggling to even get 500 patients?

"In 2016, there were 15,807 deaths among people with diagnosed HIV in the United States."

https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics

Bullboard Posts

2024, a breakthrough year for silver